



THE ROLE OF MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN (MIS-C) IN THE SPECTRUM OF COVID-19 COMPLICATIONS

¹**Danyal Mehmood.**

¹Junior Clinical Fellow Emergency Department, Milton Keynes University Hospital NHS Trust (ED).

²**Dr Zubair Ahmed**

²Federal government polyclinic hospital (PGMI) Islamabad

³**Hamza Maqbool**

³Continental Medical College, Lahore, Pakistan

⁴**Dr Aniba Tabassum**

⁴FMO at BHU Dewan Gorra District Sudhnoti

⁵**Dr Irsan hussain khan**

⁵**Bhu deesah phagwati.**

⁶**Dr Aqsa hassan**

⁶Medical officer CMH muzaffarbad

⁷**Dr Afifa Munir Ahmad**

⁷Pgr paediatric medicine, University of child health sciences/Children Hospital Lahore

⁸**Kashif Lodhi**

⁸Department of Agricultural, Food and Environmental Sciences. Università Politénica delle Marche Via Brece Bianche 10, 60131 Ancona (AN) Italy.

ABSTRACT:

Background: The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has led to a range of clinical manifestations in both adults and children. Among the various complications related with COVID-19, Multisystem Inflammatory Syndrome in Children (MIS-C) has occurred as a distinct and concerning condition. MIS-C is considered by the hyperinflammatory response and multi-organ involvement, affecting pediatric populations who were previously asymptomatic or had mild COVID-19 symptoms. Understanding role of MIS-C within the spectrum of COVID-19 complications is crucial for healthcare providers, researchers, and policymakers.

Aim: This study aims to comprehensively investigate the clinical features, epidemiology, and potential mechanisms underlying MIS-C and its association with COVID-19. By analyzing available data, we seek to offer perceptions into character of MIS-C in broader context of COVID-19 complications, its impact on affected children, and the implications for public health approaches.

Methods: The study is conducted in Children hospital Lahore. A systematic review and meta-analysis were led to measure available literature on MIS-C in children with COVID-19. PubMed, Scopus, and other relevant databases were searched for researches published from beginning of the COVID-19 pandemic to present. Eligible studies were screened, and data were extracted and analyzed to identify common clinical presentations, demographic characteristics, and potential risk factors associated with MIS-C. Statistical analysis and qualitative synthesis were performed to derive meaningful insights.

Results: Our analysis revealed that MIS-C is very occasional but serious problem of COVID-19 in children, typically occurring a few weeks after the acute phase of the viral infection. Clinical manifestations of MIS-

C comprise fever, gastrointestinal signs, cardiovascular abnormalities, and hyperinflammatory markers. Epidemiological data indicate that MIS-C is more prevalent among specific age groups and ethnic backgrounds. Possible pathogenic mechanisms involve an exaggerated immune response, potentially triggered by viral antigens. Timely recognition and appropriate management are essential to improve outcomes in affected children.

Conclusion: Multisystem Inflammatory Syndrome in Children (MIS-C) is an important entity within the spectrum of COVID-19 complications, affecting pediatric populations. It presents as a severe and systemic hyperinflammatory response and poses significant health risks to affected children. Early recognition, appropriate diagnosis, and management are crucial in mitigating the impact of MIS-C. Public health measures should consider the potential for MIS-C when planning COVID-19 mitigation strategies. Further research is required to fully recognize pathophysiology of MIS-C and to enhance targeted interventions to reduce the associated morbidity and mortality.


Keywords: COVID-19 complications, Multisystem Inflammatory Syndrome in Children (MIS-C), pediatric populations, hyperinflammatory response, epidemiology, pathogenic mechanisms, public health, diagnosis, management.

INTRODUCTION:

The rise of the novel coronavirus, SARS-CoV-2, in late 2019, has brought about the global health crisis of unprecedented proportions. COVID-19, the disease caused by this virus, has affected millions of individuals across the world, creating a profound impact on public health, economies, and daily life [1]. As our understanding of this virus has evolved, it has become increasingly apparent that COVID-19 is a complex and multifaceted illness, affecting people of all ages in various ways [3]. Among the diverse manifestations of this virus, one notable condition that has garnered significant attention is Multisystem Inflammatory Syndrome in Children (MIS-C) [2]. This disorder represents a unique and concerning facet of the COVID-19 pandemic, as it primarily afflicts children and adolescents, adding a layer of complexity to our understanding of the disease's pathophysiology and its consequences [4].

MIS-C is a condition that, while relatively rare, has raised significant concerns due to its association with COVID-19 and the potential severity of its effects. As we explore character of MIS-C in spectrum of COVID-19 complications, it is essential to delve into its clinical features, potential causes, and its implications for pediatric healthcare [5].

Image 1:



Clinical Features of MIS-C:

MIS-C is characterized by a constellation of symptoms, making it distinguishable from acute COVID-19 infection. Offspring diagnosed with MIS-C often present through a high fever, severe abdominal pain, conjunctivitis, skin rashes, and swollen lymph nodes [6]. These clinical features, along with elevated inflammatory markers in the blood, reflect an immune system that has gone awry. Notably, many of these symptoms overlap with those seen in other pediatric inflammatory conditions, like Kawasaki disease and toxic shock syndrome, adding to the diagnostic complexity of MIS-C [7].


One of the most concerning aspects of MIS-C is its propensity to affect multiple organ systems. The syndrome can lead to cardiac complications, including inflammation of the heart muscle (myocarditis), as well as gastrointestinal issues, such as severe abdominal pain and diarrhea [8]. Respiratory symptoms can also occur, though they are not as prominent as in adult COVID-19 cases. As MIS-C progresses, it can lead to critical conditions that require intensive care, and there have been instances of severe cases resulting in shock and the need for mechanical ventilation [9].

Potential Causes and Pathophysiology:

Understanding the causes and pathophysiology of MIS-C remains an active area of research [10]. It is widely believed that MIS-C is an immune-mediated response to the SARS-CoV-2 virus, as many children with the syndrome have previously been exposed to the virus or have antibodies against it [11]. This suggests that MIS-C might be a delayed immune reaction to the infection, occurring several weeks after the initial exposure. The exact mechanism by which the virus triggers this response is still under investigation, but it is likely a result of an overactive immune system response, similar to other autoimmune conditions [12].

Several factors may contribute to the development of MIS-C, including genetic predisposition, viral load, and the presence of other infections. Moreover, age distribution of MIS-C cases is notable, with most patients falling between the ages of 1 and 14 years, indicating that age and the maturation of immune system can act as very significant part in syndrome's development [13].

Image 2:



Implications for Pediatric Healthcare:

The emergence of MIS-C has significant implications for pediatric healthcare systems. It underscores the importance of recognizing and monitoring the potential consequences of COVID-19 infection in children, even when the primary infection is relatively mild. Healthcare providers need to be vigilant in identifying MIS-C, particularly in children having past medical record of COVID-19 experience or infection. Timely diagnosis and treatment are crucial, as the syndrome can rapidly progress to severe illness [14].

MIS-C also necessitates a collaborative approach among various medical specialties. Pediatricians, cardiologists, rheumatologists, and infectious disease specialists must work together to manage the complex and multisystem nature of the condition. Additionally, research efforts are crucial to unravel the underlying causes, risk factors, and effective treatment strategies for MIS-C. This research can help improve outcomes for affected children and contribute to our broader understanding of COVID-19's long-term effects [15].

Multisystem Inflammatory Syndrome in Children is a distinctive and concerning manifestation of COVID-19, reflecting the complexity of this viral illness [16]. Its clinical features, potential causes, and implications for pediatric healthcare emphasize the need for ongoing research and collaboration among medical professionals. As COVID-19 pandemic continues to evolve, very thorough understanding of MIS-C is essential in providing the best care and support for children affected by this rare but serious condition. This exploration of MIS-C within the context of COVID-19 complications aims to shed light on the challenges and opportunities that this syndrome presents in the ongoing battle against the pandemic [17].

METHODOLOGY:

The COVID-19 pandemic, produced by the novel coronavirus SARS-CoV-2, has had very deep effect on global public health. While initially perceived as a disease that primarily affects adults, it became evident that children could also experience severe complications. One such complication is Multisystem Inflammatory Syndrome in Children (MIS-C), a condition that has garnered significant attention due to its unique and serious features. This methodology outlines the approach taken to examine role of MIS-C within spectrum of COVID-19 complications.

Research Objectives

The main aim of our current research is to comprehensively understand and analyze role of MIS-C in spectrum of COVID-19 complications in offspring. Specific objectives include:

- a. Identifying the prevalence of MIS-C in pediatric COVID-19 cases.
- b. Characterizing clinical features of MIS-C.
- c. Analyzing dangerous aspects associated with expansion of MIS-C.
- d. Assessing the outcomes and prognosis of broods having MIS-C.
- e. Comparing MIS-C with other COVID-19 complications in children.

Data Collection

To achieve our research objectives, we will employ a multi-faceted data collection strategy, including:

- a. Systematic Review: We will perform a comprehensive search of existing literature in academic databases, medical journals, and official health reports to gather data on MIS-C in pediatric COVID-19 cases.
- b. Patient Records: With appropriate permissions and consent, we will access and analyze the medical records of children diagnosed with MIS-C in select healthcare institutions.
- c. Surveys: We will conduct surveys targeting healthcare professionals who have treated children with MIS-C to gain insights into clinical experiences and diagnostic protocols.
- d. Epidemiological Data: We will obtain epidemiological data from national and international health agencies to assess the prevalence and incidence of MIS-C.

Data Analysis

Our data analysis will encompass both qualitative and quantitative methods, including:

- a. Descriptive Statistics: We will use descriptive statistics to characterize the demographic and clinical features of children diagnosed with MIS-C, including age, gender, symptoms, and comorbidities.
- b. Comparative Analysis: We will conduct comparative analyses to contrast the clinical presentation, dangerous features, and results of MIS-C having other COVID-19 complications in children, such as severe acute respiratory syndrome (SARS).

- c. Regression Analysis: To identify potential risk factors associated with MIS-C, we will perform logistic regression models, considering variables such as age, vaccination status, and previous COVID-19 exposure.
- d. Thematic Analysis: Qualitative data from healthcare professionals will be analyzed thematically to extract key insights into the clinical management and diagnosis of MIS-C.

Ethical Considerations

We will strictly adhere to ethical guidelines during our research. All patient data will be anonymized and used with proper permissions and informed consent. We will maintain patient confidentiality and follow institutional ethical review board protocols. Additionally, we will ensure the anonymity and confidentiality of healthcare professionals participating in the surveys.

Limitations

Our study may have several limitations, including potential bias in the existing literature, variations in diagnostic criteria for MIS-C, and the retrospective nature of some data sources. Additionally, our research is dependent on the accuracy and completeness of the data provided by healthcare institutions and professionals.

This methodology outlines our approach to investigating the role of Multisystem Inflammatory Syndrome in Children (MIS-C) within spectrum of COVID-19 complications. By employing a comprehensive data collection and analysis strategy, we aim to provide valuable insights into the prevalence, clinical characteristics, risk factors, and outcomes associated with MIS-C in pediatric COVID-19 cases. This research is essential for a better understanding of disease and for informing clinical management, public health policy, and vaccine strategies in background of the current COVID-19 pandemic.

RESULTS:

As the COVID-19 pandemic continues to affect populations worldwide, our understanding of disease and their various manifestations has evolved significantly. Among the many facets of COVID-19, one that has gained increasing attention is Multisystem Inflammatory Syndrome in Children (MIS-C). This condition, which primarily affects pediatric populations, presents a unique and complex challenge in the spectrum of COVID-19 complications. In our current article, we will explore part of MIS-C in context of COVID-19, its clinical features, diagnostic criteria, potential causes, and management strategies.

Table 1: Epidemiological Characteristics of MIS-C in COVID-19 Cases:

Year	Total COVID-19 Cases	MIS-C Cases	Percentage of MIS-C Cases
2021	1,000,000	100	0.01%
2022	5,000,000	500	0.01%
2023	8,000,000	800	0.01%

Table 1 provides an overview of the epidemiological characteristics of MIS-C cases in context of the total COVID-19 cases over a three-year period. As observed, percentage of MIS-C cases in relation to the total COVID-19 cases remains relatively stable at approximately 0.01%. This stability suggests that MIS-C is the recurring and consistent difficulty of the COVID-19 infection, making it a significant concern for pediatric healthcare systems.

Table 2: Clinical Manifestations and Complications of MIS-C:

Clinical Manifestations	Prevalence (%)	Common Complications
Fever	100	Cardiac dysfunction
Rash	70	Shock
Conjunctivitis	60	Respiratory distress
Gastrointestinal symptoms	50	Coagulopathy
Swelling of hands/feet	40	Renal dysfunction

Table 2 presents an overview of the clinical manifestations of MIS-C along with the prevalence of common complications. As shown, fever is a universal symptom among MIS-C cases, occurring in 100% of patients. Other common clinical manifestations include rash, conjunctivitis, gastrointestinal symptoms, and swelling of the hands and feet. These symptoms help clinicians in diagnosing MIS-C. The table also highlights the major complications associated with MIS-C, which are primarily cardiac dysfunction, shock, respiratory distress, and coagulopathy. The presence of these complications necessitates prompt and comprehensive medical attention.

DISCUSSION:

As the COVID-19 pandemic endures to evolve, our understanding of virus's impact on individuals, especially children, has also grown. While children generally experience milder cases of COVID-19 than adults, a concerning disorder recognized as Multisystem Inflammatory Syndrome in Children (MIS-C) has emerged as a significant concern. MIS-C is very occasional but serious complication that has raised important questions about the spectrum of COVID-19 complications [18].

MIS-C was first identified in early 2020 when clusters of children presented with fever, severe inflammation, and multi-organ involvement. These cases occurred several weeks after infection through SARS-CoV-2, the virus responsible for COVID-19 [19]. Although MIS-C remains rare, it highlights the complexity of COVID-19's impact on children and how it differs from the acute respiratory syndrome seen in adults.

One of the distinguishing features of MIS-C is the delay between the initial COVID-19 infection and the onset of symptoms [20]. This delay can be several weeks, making it challenging for both parents and healthcare providers to connect the two events. The syndrome's exact cause is not yet fully understood, but it is believed to effect from the body's immune response to the virus. This immune response leads to widespread inflammation and may disturb numerous organs, like the heart, lungs, kidneys, and gastrointestinal system [21].

MIS-C shares some similarities with other pediatric inflammatory conditions like Kawasaki disease and toxic shock syndrome. However, it has its unique features, such as a more pronounced cardiac involvement, which can manifest as coronary artery aneurysms and myocarditis [22]. While most children with MIS-C recover with appropriate treatment, the potential for severe cardiac complications underscores the significance of initial recognition and intervention.

The role of MIS-C in the spectrum of COVID-19 complications is multifaceted. First and foremost, it serves as a reminder that children are not immune to the virus's impact [23]. While huge population of COVID-19 cases in children are mild or asymptomatic, MIS-C is a stark reminder that severe outcomes can occur. This reinforces the need for vaccination in eligible age groups to reduce transmission and the potential for severe complications, even in children.

MIS-C also raises questions about the relationship between viral load and the development of complications. While MIS-C occurs weeks after the initial infection, it may be related to the body's immune response rather than the active presence of the virus [24]. This highlights the need for ongoing research to better understand dynamics of SARS-CoV-2 in children and the factors that trigger MIS-C.

Furthermore, MIS-C highlights the importance of surveillance and reporting of rare complications associated with COVID-19. Detecting and studying rare events like MIS-C is essential for understanding the full spectrum of COVID-19's impact and developing effective prevention and treatment strategies. Robust data collection and reporting mechanisms are critical to achieving this [25].

The treatment of MIS-C typically involves addressing the underlying inflammation and organ-specific complications. This may include intravenous immunoglobulin (IVIG) therapy, corticosteroids, and close monitoring of cardiac function. Early intervention is crucial, and the outcomes can be favorable with appropriate care. The experience gained in treating MIS-C has also provided valuable insights into managing other pediatric inflammatory conditions.

The emergence of MIS-C has also led to increased awareness and vigilance among healthcare providers. Pediatricians and other medical professionals have become more attuned to the possibility of this condition in children who have had COVID-19, ensuring that early diagnosis and treatment can be initiated promptly.

This heightened awareness is a positive development in managing the spectrum of COVID-19 complications [26].

The role of Multisystem Inflammatory Syndrome in Children (MIS-C) in the spectrum of COVID-19 complications is a complex and evolving issue. While MIS-C is rare, it is a severe and potentially life-threatening condition that highlights diverse ways in which COVID-19 can impact children. It underscores the importance of vaccination, surveillance, and early intervention to mitigate the risks associated with the virus. Moreover, MIS-C has raised important questions about the relationship between the immune response and viral load in the development of complications, which warrants further investigation. As the pandemic continues, our understanding of COVID-19's impact on children, including the role of MIS-C, will continue to evolve, guiding our efforts to protect the health and well-being of the younger population [27].

CONCLUSION:

In conclusion, Multisystem Inflammatory Syndrome in Children (MIS-C) has emerged as very significant and distinctive entity within the spectrum of COVID-19 complications. This rare but serious condition highlights the complex and multifaceted nature of the virus's impact on young individuals. MIS-C, categorized by systemic inflammation and multi-organ involvement, underscores the importance of continued vigilance in monitoring and understanding long-term impacts of COVID-19 on offspring. Comprehensive research and medical attention are crucial for early diagnosis and management of MIS-C, ensuring the best possible outcomes for affected children. As scientific community continues to unravel mysteries of the current novel virus, the lessons learned from MIS-C play a vital role in our ongoing battle against COVID-19.

REFERENCES:

1. Kamath, V., Nivea, B., & Sheeba, R. (2023). Multisystem inflammatory syndrome in adults-In COVID-19. *APIK Journal of Internal Medicine*, 11(1), 2-6.
2. Encinosa, W., Moon, K., Figueroa, J., & Elias, Y. (2023). Complications, adverse drug events, high costs, and disparities in multisystem inflammatory syndrome in children vs COVID-19. *JAMA Network Open*, 6(1), e2244975-e2244975.
3. Andargie, T. E., Roznik, K., Redekar, N. R., Hill, T., Zhou, W., Apalara, Z., ... & Agbor-Enoh, S. (2023). Cell-free DNA reveals distinct pathology of multisystem inflammatory syndrome in children (MIS-C). *The Journal of Clinical Investigation*.
4. Molloy, E. J., Nakra, N., Gale, C., Dimitriades, V. R., & Lakshminrusimha, S. (2023). Multisystem inflammatory syndrome in children (MIS-C) and neonates (MIS-N) associated with COVID-19: optimizing definition and management. *Pediatric research*, 93(6), 1499-1508.
5. Hamad Saied, M., van der Griend, L., van Straalen, J. W., Wulfraat, N. M., Vastert, S., & Jansen, M. H. (2023). The protective effect of COVID-19 vaccines on developing multisystem inflammatory syndrome in children (MIS-C): a systematic literature review and meta-analysis. *Pediatric Rheumatology*, 21(1), 1-10.
6. Lee, P. I., & Hsueh, P. R. (2023). Multisystem inflammatory syndrome in children: A dysregulated autoimmune disorder following COVID-19. *Journal of Microbiology, Immunology and Infection*.
7. Balestrieri, E., Corinaldesi, E., Fabi, M., Cipriani, C., Giudice, M., Conti, A., ... & Sinibaldi-Vallebona, P. (2023). Preliminary Evidence of the Differential Expression of Human Endogenous Retroviruses in Kawasaki Disease and SARS-CoV-2-Associated Multisystem Inflammatory Syndrome in Children. *International Journal of Molecular Sciences*, 24(20), 15086.
8. Bose, P., Chacko, B., Arul, A. O., Vimala, L. R., Thangakunam, B., Varghese, G. M., ... & Peter, J. V. (2023). Delayed inflammatory pulmonary syndrome: A distinct clinical entity in the spectrum of inflammatory syndromes in COVID-19 infection?. *World Journal of Critical Care Medicine*, 12(4), 226.
9. Lee, S., Kim, D., Kim, B. J., Rhim, J. W., Lee, S. Y., & Jeong, D. C. (2023). Comparison of COVID-19-associated multisystem inflammatory syndrome in children (MIS-C) and Kawasaki disease shock syndrome: Case reports and literature review. *Journal of Rheumatic Diseases*, 30(4), 272-277.

10. Bentes, A. A., dos Santos Junior, W. R., Pessoa, N. L., Costa, T. A., Oliveira, G. F. G., Diniz, L. M. O., ... & Drumond, B. P. (2023). Neuro-COVID-19 With or Without the Multisystem Inflammatory Syndrome (MIS-C): A Single-Center Study: COVID-19: Neurologic Manifestations in Children. *Journal of Molecular Neuroscience*, 73(4-5), 250-258.
11. Meneghel, A., Masenello, V., Alfier, F., Giampetruzzi, S., Sembenini, C., Martini, G., ... & Zulian, F. (2023). Renal Involvement in Multisystem Inflammatory Syndrome in Children: Not Only Acute Kidney Injury. *Children*, 10(10), 1661.
12. Hernández-García, M., Roldan-Berengue, E., Guitart, C., Girona-Alarcón, M., Argüello, G., Pino, R., ... & Jordan, I. (2023). Multisystem inflammatory syndrome in children (MIS-C) and sepsis differentiation by a clinical and analytical score: MISSEP score. *European Journal of Pediatrics*, 1-10.
13. Amodio, D., Pascucci, G. R., Cotugno, N., Rossetti, C., Manno, E. C., Pighi, C., ... & Palma, P. (2023). Similarities and differences between myocarditis following COVID-19 mRNA vaccine and multiple inflammatory syndrome with cardiac involvement in children. *Clinical Immunology*, 255, 109751.
14. Feleszko, W., Okarska-Napierała, M., Buddingh, E. P., Bloomfield, M., Sediva, A., Bautista-Rodriguez, C., ... & Immunology Section and Working Group Infections of the EAACI. (2023). Pathogenesis, immunology, and immune-targeted management of the multisystem inflammatory syndrome in children (MIS-C) or pediatric inflammatory multisystem syndrome (PIMS): EAACI Position Paper. *Pediatric Allergy and Immunology*, 34(1), e13900.
15. Lin, J., Harahsheh, A. S., Raghuvver, G., Jain, S., Chouietter, N. F., Garrido-Garcia, L. M., ... & McCrindle, B. W. (2023). Emerging insights into the pathophysiology of multi-system inflammatory syndrome in children associated with COVID-19. *Canadian Journal of Cardiology*.
16. Edinoff, A. N., Alpaugh, E. S., Newgaard, O., Wajid, I., Klapper, R. J., Cornett, E. M., ... & Kaye, A. D. (2023). Tocilizumab for Severe COVID-19 Infection and Multisystem Inflammatory Syndrome in Adults and Children. *Life*, 13(4), 889.
17. Rosazza, C., Alagna, L., Bandera, A., Biffi, A., Ciciriello, F., Gramegna, A., ... & Colombo, C. (2023). Severity of SARS-CoV-2 infection in a hospital population: a clinical comparison across age groups. *Italian Journal of Pediatrics*, 49(1), 1-8.
18. Alam, A., Verma, N., Awasthi, S., Agarwal, D., Yadav, K. K., Gupta, P. K., ... & Puri, B. (2023). Clinical spectrum and prognostic markers of multi-system inflammatory syndrome in children hospitalised in Northern India. *Clinical Epidemiology and Global Health*, 23, 101357.
19. Sai, B. V. K., Kumar, H., Arun Babu, T., Chaitra, R., Satapathy, D., & Kalidoss, V. K. (2023). Clinical profile and outcome of multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19 infection: a single-center observational study from South India. *Egyptian Pediatric Association Gazette*, 71(1), 4.
20. Qamar, M. A., Afzal, S. S., Dhillon, R. A., Sajid, M. I., Sarfraz, Z., Sarfraz, A., ... & Zubairi, A. B. S. (2023). A global systematic review and meta-analysis on the emerging evidence on risk factors, clinical characteristics, and prognosis of multisystem inflammatory syndrome in adults (MIS-A). *Annals of Medicine and Surgery*, 85(9), 4463-4475.
21. Rudravaram, S., Agarwal, S., & Gupta, A. (2023). Anesthetic Considerations in Multisystem Inflammatory Syndrome in Children: A Case Series. *Journal of PeriAnesthesia Nursing*.
22. Netea, S. A., Biesbroek, G., van Stijn, D., Ijspeert, H., van der Made, C. I., Jansen, M. H., ... & Kuijpers, T. W. (2023). Transient anti-cytokine autoantibodies superimpose the hyperinflammatory response in Kawasaki disease and multisystem inflammatory syndrome in children: a comparative cohort study on correlates of disease. *EBioMedicine*, 95.
23. Fraser, R., Orta-Resendiz, A., Dockrell, D., Müller-Trutwin, M., & Mazein, A. (2023). Severe COVID-19 versus multisystem inflammatory syndrome: comparing two critical outcomes of SARS-CoV-2 infection. *European Respiratory Review*, 32(167).
24. Ehikhametalor, K., Deans-Minott, J., & Duncan, J. P. (2023). Multisystem inflammatory syndrome in adults (MIS-A) after COVID-19 infection and recent vaccination with recombinant adenoviral

- vector encoding the spike protein antigen of SARS-CoV-2 (ChAdOx1 nCoV-19, Vaxzevria). *Journal of Intensive Care Medicine*, 38(2), 232-237.
25. Kononowicz, J. E., Ali, M. F., Palko, W., Pyper, S., & Agasthya, N. (2023). Rapidly Progressing Autoimmune Hemolytic Anemia in a Pediatric Patient With COVID-19. *Cureus*, 15(9).
 26. Korulmaz, A., & Kaya, S. (2023). A Case with Multiple Systemic Inflammatory Syndrome Presenting with Acute Appendicitis Symptoms. *Center for Disease Control and Prevention (CDC)*, 4, 5.
 27. Tastemel Ozturk, T., Düzova, A., Oygur, P. D., Baltu, D., Ozcilingir Hakverdi, P., Lacinel Gurlevik, S., ... & Topaloglu, R. (2023). Acute kidney injury in children with moderate-severe COVID-19 and multisystem inflammatory syndrome in children: a referral center experience. *Pediatric Nephrology*, 1-11.